Overview

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

Status:
Completed
Trial end date:
2020-08-10
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.
Phase:
Phase 3
Details
Lead Sponsor:
Avedro, Inc.
Glaukos Corporation
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Riboflavin